InnoCan Pharma Statistics
Total Valuation
InnoCan Pharma has a market cap or net worth of 86.58 million. The enterprise value is 83.28 million.
| Market Cap | 86.58M |
| Enterprise Value | 83.28M |
Important Dates
The next estimated earnings date is Thursday, November 20, 2025.
| Earnings Date | Nov 20, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 6.04M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +7.00% |
| Shares Change (QoQ) | +0.66% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 5.12M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.00 |
| PB Ratio | 12.94 |
| P/TBV Ratio | 20.58 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 241.92, with an EV/FCF ratio of -177.56.
| EV / Earnings | -52.84 |
| EV / Sales | 2.95 |
| EV / EBITDA | 241.92 |
| EV / EBIT | 267.79 |
| EV / FCF | -177.56 |
Financial Position
The company has a current ratio of 3.70, with a Debt / Equity ratio of 0.21.
| Current Ratio | 3.70 |
| Quick Ratio | 2.70 |
| Debt / Equity | 0.21 |
| Debt / EBITDA | 3.97 |
| Debt / FCF | -2.98 |
| Interest Coverage | 26.50 |
Financial Efficiency
Return on equity (ROE) is -4.84% and return on invested capital (ROIC) is 2.81%.
| Return on Equity (ROE) | -4.84% |
| Return on Assets (ROA) | 2.01% |
| Return on Invested Capital (ROIC) | 2.81% |
| Return on Capital Employed (ROCE) | 3.93% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | 5 |
| Asset Turnover | 2.92 |
| Inventory Turnover | 1.26 |
Taxes
In the past 12 months, InnoCan Pharma has paid 937,000 in taxes.
| Income Tax | 937,000 |
| Effective Tax Rate | 148.97% |
Stock Price Statistics
The stock price has increased by +121.62% in the last 52 weeks. The beta is -0.43, so InnoCan Pharma's price volatility has been lower than the market average.
| Beta (5Y) | -0.43 |
| 52-Week Price Change | +121.62% |
| 50-Day Moving Average | 10.88 |
| 200-Day Moving Average | 25.80 |
| Relative Strength Index (RSI) | 57.36 |
| Average Volume (20 Days) | 176 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, InnoCan Pharma had revenue of 28.83 million and -1.58 million in losses. Loss per share was -0.36.
| Revenue | 28.83M |
| Gross Profit | 25.50M |
| Operating Income | 318,000 |
| Pretax Income | 629,000 |
| Net Income | -1.58M |
| EBITDA | 352,000 |
| EBIT | 318,000 |
| Loss Per Share | -0.36 |
Balance Sheet
The company has 7.26 million in cash and 1.40 million in debt, giving a net cash position of 5.86 million.
| Cash & Cash Equivalents | 7.26M |
| Total Debt | 1.40M |
| Net Cash | 5.86M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 6.69M |
| Book Value Per Share | 0.93 |
| Working Capital | 7.98M |
Cash Flow
In the last 12 months, operating cash flow was -453,000 and capital expenditures -16,000, giving a free cash flow of -469,000.
| Operating Cash Flow | -453,000 |
| Capital Expenditures | -16,000 |
| Free Cash Flow | -469,000 |
| FCF Per Share | n/a |
Margins
Gross margin is 88.45%, with operating and profit margins of 1.10% and -5.47%.
| Gross Margin | 88.45% |
| Operating Margin | 1.10% |
| Pretax Margin | 2.18% |
| Profit Margin | -5.47% |
| EBITDA Margin | 1.22% |
| EBIT Margin | 1.10% |
| FCF Margin | n/a |
Dividends & Yields
InnoCan Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.00% |
| Shareholder Yield | n/a |
| Earnings Yield | -1.82% |
| FCF Yield | -0.54% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on September 5, 2025. It was a reverse split with a ratio of 0.0153846.
| Last Split Date | Sep 5, 2025 |
| Split Type | Reverse |
| Split Ratio | 0.0153846 |
Scores
InnoCan Pharma has an Altman Z-Score of 4.9 and a Piotroski F-Score of 3.
| Altman Z-Score | 4.9 |
| Piotroski F-Score | 3 |